NVTR - Book Build Alert: Axonics Modulation Readies IPO In Challenging Market
Quick Take
The Axonics Modulation (AXNX) IPO is indicating significant demand according to IPO information service IPO Boutique.
Axonics sells a sacral neuromodulation system for the treatment of several urinary conditions.
Although life science firms may be somewhat less affected by short-term market volatility, interested investors in AXNX might be wise to keep the stock on a watch list for a potential lower entry point post-IPO.
Background
Axonics has developed a minimally invasive rechargeable SNM (r-SNM) system for patients with overactive bladder [OAB], fecal incontinence [FI], and urinary retention [UR].
AMT has developed